MetaCap

Biomea Fusion (BMEA) vs Intercure (INCR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biomea Fusion (BMEA) has outperformed Intercure (INCR) over the past year, losing 41.5% versus a loss of 50.6%. Over five years, INCR leads with a -90.9% price change compared with -95.2% for BMEA. Intercure is the larger company by market cap ($42.0 million vs $41.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BMEA-41.51%INCR-50.57%
+134%+37%-59%
Nov 21, 20251 yearNov 20, 2026
BMEA-94.67%INCR-91.77%
+298%+92%-113%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BMEA versus INCR key metrics
MetricBMEAINCR
Share price$0.5744$3.24
Market cap$41.75M$42.03M
1-day change-2.38%-7.69%
YTD return-53.68%-28.79%
1-year return-41.51%-50.57%
5-year return-95.21%-90.87%
EPS (TTM)$-0.10$-0.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-61.80M—
52-week high$2.24$7.55
52-week low$0.45$3.12
Distance from 52-week high-74.32%-57.09%
Analyst consensusbuy—
Avg. price target upside+1118.66%—
Average volume2.22M15.93K
Shares outstanding72.68M12.97M
Employees37285
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Biomea Fusion

BMEA stock →

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees

About Intercure

INCR stock →

InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.

Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees

BMEA vs INCR FAQ

Which is bigger, Biomea Fusion or Intercure?

Intercure (INCR) is larger, with a market capitalization of $42.03M compared with $41.75M for Biomea Fusion (BMEA).

Which stock has performed better over the past year, BMEA or INCR?

BMEA returned -41.51% over the past 12 months, compared with -50.57% for INCR (price return, excluding dividends). Past performance does not predict future results.

Are Biomea Fusion and Intercure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons